Modern Methods for Breast Cancer Diagnosis and Classification: A Current Update

PDF

Published: 2023-09-06

DOI: 10.56557/upjoz/2023/v44i193635

Page: 189-204


Shaik Asha Begum *

IPT, SPMVV, TIRUPATI and Nirmala College of Pharmacy, Atmakur. Mangalagiri, Andhra Pradesh, India.

S. Joshna Rani

IPT, SPMVV, TIRUPATI, Andhra Pradesh, India.

Veena Yeruva

Nirmala College of Pharmacy, Atmakur, Mangalagiri, AP, India.

*Author to whom correspondence should be addressed.


Abstract

The incidence of cancer-related deaths worldwide has increased by 66% since 1960, according to the International Agency for Research on Cancer (IARC). A breast cancer diagnosis is predicted to occur in one in eight women in the US alone at some point in their lifetime. A BC diagnosis is typically made using high-end molecular bioimaging, ultrasound, and mammography. Unfortunately, these methods only discover BC after the fact. So there is still a need for both early and sophisticated molecular diagnostic techniques. Numerous histological and immuno-molecular studies conducted during the past ten years have shown that BC is exceedingly diverse in nature. Its cytological characteristics, growth pattern, and expression of important biomarkers in BC cells, such as hormone receptor markers, can be used to create cutting-edge diagnostic and treatment tools. Compositions, intracellular and extracellular environments, depth, shape, and structure of the cells. Currently, BC is treated with surgery, systemic chemotherapy, and focused radiation therapy. In order to determine the heterogeneity and recurrence score, which fully identifies the BC subtype at issue, a biopsied sample is next subjected to a number of multigene assays. We currently have seven prognostic multigene signature tests for BC that offer a risk profile that can spare low-risk patients from unnecessary treatments. Clinicopathological data should be integrated with genomic-imprint analysis, according to numerous comparative studies on multigene analysis. There is a good chance that current cohort studies like MINDACT, TAILORx, Trans-aTTOM, and many others will have a favourable effect on patient outcomes over the long term. This review presents a compendium of data on BC diagnoses and available therapies. The development of sophisticated biomarkers is also described.

Keywords: Breast cancer, mammography, BRCA genes, early detection, biomarkers of BC


How to Cite

Begum , S. A., Rani , S. J., & Yeruva , V. (2023). Modern Methods for Breast Cancer Diagnosis and Classification: A Current Update. UTTAR PRADESH JOURNAL OF ZOOLOGY, 44(19), 189–204. https://doi.org/10.56557/upjoz/2023/v44i193635

Downloads

Download data is not yet available.

References

Alix-Panabières C, Pantel K. Challenges in circulating tumour cell research. Nat. Rev. Cancer. 2014;14(9):623–631. DOI: 10.1038/nrc3820

Alzurq E, Almaktari A, Aldin B, Hamoud M, Othman S. New system for early breast cancer detection by Electrical impedance spectroscopy. Recent Adv. Environ. Sci. Biomed. 2016;4:142–150.

Amioka A, Masumoto N, Gouda N, Kajitani K, Shigematsu H, Emi A, et al. Ability of contrast-enhanced ultrasonography to determine clinical responses of breast cancer to neoadjuvant chemotherapy. Jpn. J. Clin. Oncol. 2016;46(4):303–309. DOI: 10.1093/jjco/hyv215

Anbar M. Clinical thermal imaging today. IEEE Eng. Med. Biol. Mag. 1998;17(4):25–33. DOI: 10.1109/51.687960

Andre F, Ismaila N, Henry NL, Somerfield MR, Bast RC, Barlow W, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO clinical practice guideline update-integration of results from TAILORx. J. Clin. Oncol. 2019;37(22):1956–1964. DOI: 10.1200/JCO.19.00945

Anglian Breast Cancer Study Group. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br. J. Cancer. 2000;83(10):1301. DOI: 10.1054/bjoc.2000.1407

Arizti P, Fang L, Park I, Yin Y, Solomon E, Ouchi T, et al. Tumor suppressor p53 is required to modulate BRCA1 expression. Mol. Cell Biol. 2000;20(20):7450– 7459. DOI: 10.1128/mcb.20.20.7450-7459.2000

Arkan E, Saber R, Karimi Z, Shamsipur M. A novel antibody-antigen based impedimetric immunosensor for low level detection of HER2 in serum samples of breast cancer patients via modification of a gold nanoparticles decorated multiwall carbon nanotube-ionic liquid electrode. Anal. Chim. Acta. 2015;874:66–74. DOI: 10.1016/j.aca.2015.03.022

Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: Current status and future perspectives. Nat. Rev. Clin. Oncol. 2012;9(1):16–32. DOI: 10.1038/nrclinonc.2011.177

Arya SK, Wang KY, Wong CC, Rahman AR. Anti-EpCAM modified LC-SPDP monolayer on gold microelectrode based electrochemical biosensor for MCF-7 cells detection. Biosens. Bioelectron. 2013;41: 446–451. DOI: 10.1016/j.bios.2012.09.006

Atwood C, Hovey R, Glover J, Chepko G, Ginsburg E, Robison W, et al. Progesterone induces side-branching of the ductal epithelium in the mammary glands of peripubertal mice. J. Endocrinol. 2000;167(1):39–52. DOI: 10.1677/joe.0.1670039

Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat. Biotechnol. 2013; 31(6):539–544. DOI: 10.1038/nbt.2576

Barazi H, Gunduru M. Mammography BI. RADS grading. StatPearls. Treasure Island, FL: StatPearls Publishing; 2019.

Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol. 2003;21(10): 1973–1979. DOI: 10.1200/JCO.2003.09.099

Bartlett J, Sgroi DC, Treuner K, Zhang Y, Piper T, Salunga RC, et al. HER2 status and prediction of extended endocrine benefit with breast cancer index (BCI) in HR+ patients in the adjuvant tamoxifen: to offer more?(aTTom) trial. J. Clin. Oncol. 2020;38(15_suppl):522. DOI: 10.1200/JCO.2020.38.15_suppl.522

Bartlett JM, Thomas J, Ross DT, Seitz RS, Ring BZ, Beck RA, et al. Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. Breast Cancer Res. 2010;12(4):R47. DOI: 10.1186/bcr2604

Begam N, Jamil K, Raju SG. Promoter hypermethylation of the ATM gene as a novel biomarker for breast cancer. Asian Pac. J. Cancer Prev. APJCP. 2017; 18(11):3003. DOI: 10.22034/APJCP.2017.18.11.3003

Behling KC, Tang A, Freydin B, Chervoneva I, Kadakia S, Schwartz GF, et al. Increased SIAH expression predicts ductal carcinoma in situ (DCIS) progression to invasive carcinoma. Breast Cancer Res. Treat. 2011;129 (3):717– 724. DOI: 10.1007/s10549-010-1254-8

Benvidi A, Dehghani Firouzabadi A, Dehghan Tezerjani M, Moshtaghiun SM, Mazloum-Ardakani M, Ansarin A. A highly sensitive and selective electrochemical DNA biosensor to diagnose breast cancer. J. Electroanalytical Chem. 2015;750:57–64. DOI: 10.1016/j.jelechem.2015.05.002

Bertwistle D, Swift S, Marston NJ, Jackson LE, Crossland S, Crompton MR, et al. Nuclear location and cell cycle regulation of the BRCA2 protein. Cancer Res. 1997;57(24):5485–5488.

Blanco-Prieto S, Barcia-Castro L, Páez de la Cadena M, Rodríguez-Berrocal FJ, Vázquez-Iglesias L, Botana-Rial MI, et al. Relevance of matrix metalloproteases in non-small cell lung cancer diagnosis. BMC Cancer. 2017;17(1):823. DOI: 10.1186/s12885-017-3842-z

Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE, Jacobs SA, et al. Anthracyclines in early breast cancer: The ABC trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG oncology). J. Clin. Oncol. 2017;35(23): 2647. DOI: 10.1200/JCO.2016.71.4147

Boriachek K, Islam MN, Gopalan V, Lam AK, Nguyen NT, Shiddiky MJA. Quantum dot-based sensitive detection of disease specific exosome in serum. Analyst. 2017;142(12):2211–2219. DOI: 10.1039/c7an00672a

Bourdon JC, Khoury MP, Diot A, Baker L, Fernandes K, Aoubala M, et al. p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res. 2011;13(1):R7. DOI: 10.1186/bcr2811

Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic density and the risk and detection of breast cancer. N. Engl. J. Med. 2007;356(3):227–236. DOI: 10.1056/NEJMoa062790

Brekelmans C, Seynaeve C, Menke-Pluymers M, Brüggenwirth H, Tilanus-Linthorst M, Bartels C, et al. Survival and prognostic factors in BRCA1-associated breast cancer. Ann. Oncol. 2006;17(3): 391–400. DOI: 10.1093/annonc/mdj095

Brekelmans C, Tilanus-Linthorst M, Seynaeve C, vd Ouweland A, Menke-Pluymers MB, Bartels CC, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur. J. Cancer. 2007;43(5): 867–876. DOI: 10.1016/j.ejca.2006.12.009

Brem RF, Tabár L, Duffy SW, Inciardi MF, Guingrich JA, Hashimoto BE, et al. Assessing improvement in detection of breast cancer with three-dimensional automated breast US in women with dense breast tissue: the SomoInsight Study. Radiology. 2015;274(3):663–673. DOI: 10.1148/radiol.14132832

Brisken C. Hormonal control of alveolar development and its implications for breast carcinogenesis. J. Mammary Gland Biol. Neoplasia. 2002;7(1):39–48. DOI: 10.1023/a:1015718406329

Brown R, Hann C, Chase JG, Ray L. Discrete color-based Euclidean-invariant signatures for feature tracking in a DIET breast cancer screening system. Med. Imaging 2007: Physiol. Funct. Struct. Med. Images, Int. Soc. Opt. Photon. 2007;6511: 65110D. DOI: 10.1117/12.711815

Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin. Cancer Res. 2015;21(7):1688–1698. DOI: 10.1158/1078-0432.CCR-14-0432

Bussolati G, Badve S. Carcinomas with neuroendocrine features, in WHO Classification of Tumours of the Breast. Editors S. R. Lakhani, I. O. Ellis, S. J. Schnitt, P. H. Tan, and M. J. van de Vijver (Lyon, France: IARC Press). 2012;62–63.

Cai K, Xu HN, Singh A, Moon L, Haris M, Reddy R, et al. Breast cancer redox heterogeneity detectable with chemical exchange saturation transfer (CEST) MRI. Mol. Imaging Biol. 2014;16(5):670–679. DOI: 10.1007/s11307-014-0739-y

Cardoso F, van’t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N. Engl. J. Med. 2016;375(8):717–729. DOI: 10.1056/NEJMoa1602253

Cardoso F, van’t Veer L, Poncet C, Lopes Cardozo J, Delaloge S, Pierga JY, et al. MINDACT: long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients. Am. Soc. Clin. Oncol. 2020;38: 506. DOI: 10.1200/JCO.2020.38.15_suppl.506

Casás-Selves M, DeGregori J. How cancer shapes evolution and how evolution shapes cancer. Evo. Edu. Outreach. 2011; 4(4):624–634. DOI: 10.1007/s12052-011-0373-y

Chambers JP, Arulanandam BP, Matta LL, Weis A, Valdes JJ. Biosensor recognition elements. Curr. Issues Mol. Biol. 2008; 10:1–12. DOI: 10.1007/978-0-387-75936-4_1

Chang RF, Chen HH, Chang YC, Huang CS, Chen JH, Lo CM. Quantification of breast tumor heterogeneity for ER status, HER2 status, and TN molecular subtype evaluation on DCE-MRI. Magn. Reson. Imaging. 2016;34(6):809–819. DOI: 10.1016/j.mri.2016.03.001

Chang YF, Hung SH, Lee YJ, Chen RC, Su LC, Lai CS, et al. Discrimination of breast cancer by measuring prostate-specific antigen levels in women's serum. Anal. Chem. 2011;83(13):5324–5328. DOI: 10.1021/ac200754x

Chauveau N, Hamzaoui L, Rochaix P, Rigaud B, Voigt J, Morucci J. Ex vivo discrimination between normal and pathological tissues in human breast surgical biopsies using bioimpedance spectroscopy. Ann. N. Y Acad. Sci. 1999; 873(1):42–50. DOI: 10.1111/j.1749-6632.1999.tb09447.x

Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. JNCI: J. Natl. Cancer Inst. 2009;101(10):736–750. doi:10.1093/jnci/djp082

Chen L, Zhang J, He Y, Ding XY. Matrix metalloproteinase-9 expression of GCTSC in peripheral tissue and central tissue of GCTB. J. Cell Biochem. 2018;119(7): 5805–5812. DOI: 10.1002/jcb.26766

Chen Y, Farmer AA, Chen CF, Jones DC, Chen PL, Lee WH. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res. 1996; 56(14):3168–3172.

Cheng AK, Su H, Wang YA, Yu HZ. Aptamer-based detection of epithelial tumor marker mucin 1 with quantum dot-based fluorescence readout. Anal. Chem. 2009;81(15):6130–6139. DOI: 10.1021/ac901223q

Cheng F, Wang Z, Huang Y, Duan Y, Wang X. Investigation of salivary free amino acid profile for early diagnosis of breast cancer with ultra performance liquid chromatography-mass spectrometry. Clin. Chim. Acta. 2015;447:23–31. DOI: 10.1016/j.cca.2015.05.008

Chia K, O’Brien M, Brown M, Lim E. Targeting the androgen receptor in breast cancer. Curr. Oncol. Rep. 2015;17(2):4. DOI: 10.1007/s11912-014-0427-8

Chun L, Kim SE, Cho M, Choe WS, Nam J, Lee DW, Lee Y. Electrochemical detection of HER2 using single stranded DNA aptamer modified gold nanoparticles electrode. Sensors Actuators B: Chem. 2013;186:446–450. DOI: 10.1016/j.snb.2013.06.046

Clark L. Monitor and control of blood and tissue oxygen tensions ASAIO J. 1956; 2(1):41–48.

Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J. Clin. Oncol. 2015; 33(4):304. DOI: 10.1200/JCO.2014.57.1414

Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, et al. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res. 2010;12(3):R40–R12. DOI: 10.1186/bcr2594

Creighton CJ, Kent Osborne C, van de Vijver MJ, Foekens JA, Klijn JG, Horlings HM, et al. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res. Treat. 2009;114(2):287–299. DOI: 10.1007/s10549-008-0017-2

Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsche HA, Islam R, et al. Circulating tumor cells in metastatic breast cancer: Biologic staging beyond tumor burden. Clin. Breast Cancer 2007;7(6): 471–479. DOI: 10.3816/cbc.2007.n.004

Cui M, Wang Y, Wang H, Wu Y, Luo X. A label-free electrochemical DNA biosensor for breast cancer marker BRCA1 based on self-assembled antifouling peptide monolayer. Sensors Actuators B: Chem. 2017;244:742–749. DOI: 10.1016/j.snb.2017.01.060

Cui X, Schiff R, Arpino G, Osborne CK, Lee AV. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J. Clin. Oncol. 2005;23(30):7721–7735. DOI: 10.1200/JCO.2005.09.004

Culha M, Stokes DL, Griffin GD, Vo-Dinh T. Application of a miniature biochip using the molecular beacon probe in breast cancer gene BRCA1 detection. Biosens. Bioelectron. 2004;19(9):1007–1012.

DOI: 10.1016/j.bios.2003.09.006

Cuzick J, Dowsett M, Pineda S, Wale C, Salter J, Quinn E, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. J. Clin. Oncol. 2011;29(32):4273–4278. DOI: 10.1200/JCO.2010.31.2835

Darlix A, Lamy PJ, Lopez-Crapez E, Braccini AL, Firmin N, Romieu G, et al. Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: Predictive biomarkers for brain metastases? Int. J. Cancer. 2016; 139(10):2299–2311. DOI: 10.1002/ijc.30290

Deng CX. BRCA1: Cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res. 2006;34(5):1416–1426. DOI: 10.1093/nar/gkl010

Dey D, Goswami T. Optical biosensors: A revolution towards quantum nanoscale electronics device fabrication, J. Biomed. Biotechnol. 2011;2011:348218. DOI: 10.1155/2011/348218

Dillenburg CV, Bandeira IC, Tubino TV, Rossato LG, Dias ES, Bittelbrunn AC, et al. Prevalence of 185delAG and 5382insC mutations in BRCA1, and 6174delT in BRCA2 in women of Ashkenazi Jewish origin in southern Brazil. Genet. Mol. Biol. 2012;35(3):599–602. DOI: 10.1590/S1415-47572012000400009

Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A’hern R, et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann. Oncol. 2006;17(5):818–826. DOI: 10.1093/annonc/mdl016

Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J. Clin. Oncol. 2013; 31(22):2783–2790. DOI: 10.1200/JCO.2012.46.1558

Dziembowska M, Wlodarczyk J. MMP9: A novel function in synaptic plasticity. Int. J. Biochem. Cell Biol. 2012;44(5):709–713. DOI: 10.1016/j.biocel.2012.01.023

Eletxigerra U, Martinez-Perdiguero J, Merino S, Barderas R, Torrente-Rodríguez R, Villalonga R, et al. Amperometric magnetoimmunosensor for ErbB2 breast cancer biomarker determination in human serum, cell lysates and intact breast cancer cells. Biosens. Bioelectron. 2015; 70:34–41. DOI: 10.1016/j.bios.2015.03.017

Ellis I, Pinder S, Bobrow L, Buley I, Coyne J, Going J, et al. Pathology reporting of breast disease. London, United Kingdom: NHS Publications; 2005.

Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol. 2001;19(18):3808–3816. DOI: 10.1200/JCO.2001.19.18.3808

Ellis, MJ, Tao Y, Young O, White S, Proia AD, Murray J, et al. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J. Clin. Oncol. 2006;24(19):3019–3025. DOI: 10.1200/JCO.2005.04.3034

Evans D, Howell A, Ward D, Lalloo F, Jones J, Eccles D. Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. J. Med. Genet. 2011;48(8): 520–522. DOI: 10.1136/jmedgenet-2011-100006

Felizi RT, Veiga MG, Carelli Filho I, Souto RPD, Fernandes CE, Oliveira E. Association between matrix metallopeptidase 9 polymorphism and breast cancer risk. Rev. Bras Ginecol Obstet. 2018;40(10):620–624. DOI: 10.1055/s-0038-1673366

Feng L, Chen Y, Ren J, Qu X. A graphene functionalized electrochemical aptasensor for selective label-free detection of cancer cells. Biomaterials. 2011;32(11):2930–2937. DOI: 10.1016/j.biomaterials.2011.01.002

Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin. Cancer Res. 2011;17(18):6012–6020. DOI: 10.1158/1078-0432.CCR-11-0926

Filipits M, Dubsky PC, Rudas M, Brase JC, Kronenwett R, Weber KE, et al. Impact of the EndoPredict-clin score on risk stratification in ER-positive, HER2-negative breast cancer after considering clinical guidelines, Am. Soc. Clin. Oncol. 2012; 30(15):542. DOI: 10.1200/jco.2012.30.15_suppl.542

Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl. Cancer Inst. 2003;95(19):1482–1485. DOI: 10.1093/jnci/djg050

Freitas M, Neves MMPS, Nouws HPA, Delerue-Matos C. Quantum dots as nanolabels for breast cancer biomarker HER2-ECD analysis in human serum. Talanta. 2020;208:120430. DOI: 10.1016/j.talanta.2019.120430

Fujita T, Doihara H, Kawasaki K, Takabatake D, Takahashi H, Washio K, et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br. J. Cancer. 2006;94(2):247–252. DOI: 10.1038/sj.bjc.6602926

Ganau S, Andreu FJ, Escribano F, Martín A, Tortajada L, Villajos M, et al. Shear-wave elastography and immunohisto chemical profiles in invasive breast cancer: Evaluation of maximum and mean elasticity values. Eur. J. Radiol. 2015; 84(4):617–622. DOI: 10.1016/j.ejrad.2014.12.020

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci. Signal. 2013;6:pl1. DOI: 10.1126/scisignal.2004088

Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011; 278(1):16–27. DOI: 10.1111/j.1742-4658.2010.07919.x

Gibson GR, Qian D, Ku JK, Lai LL. Metaplastic breast cancer: clinical features and outcomes. Am. Surg. 2005;71(9):725–730. DOI: 10.1177/000313480507100906

Godet I, Gilkes DM. BRCA1 and BRCA2 mutations and treatment strategies for breast cancer. Integr. Cancer Sci. Ther. 2017;4. DOI: 10.15761/ICST.1000228

Golubnitschaja O, Yeghiazaryan K, Abraham JA, Schild HH, Costigliola V, Debald M, et al. Breast cancer risk assessment: A non-invasive multiparametric approach to stratify patients by MMP-9 serum activity and RhoA expression patterns in circulating leucocytes. Amino Acids. 2017;49(2):273–281. DOI: 10.1007/s00726-016-2357-2

Goto Y, De Silva M, Toscani A, Prabhakar B, Notkins A, Lan M. A novel human insulinoma-associated cDNA, IA-1, encodes a protein with zinc-finger DNA-binding motifs. J. Biol. Chem. 1992; 267(21):15252–15257. DOI: 10.1016/s0021-9258(18)42173-4

Grieshaber D, MacKenzie R, Vörös J, Reimhult E. Electrochemical biosensors—sensor principles and architectures. Sensors (Basel). 2008;8(3):1400– 1458. DOI: 10.3390/s80314000

Haeri Z, Shokoufi M, Jenab M, Janzen R, Golnaraghi F. Electrical impedance spectroscopy for breast cancer diagnosis: Clinical study. Integr. Cancer Sci. Ther. 2016;3(6):1–6. DOI: 10.15761/icst.1000212

Salvo N, Barnes E, van Draanen J, et al. Prophylaxis and management of acute radiation-induced skin reactions: A systematic review of the literature. Curr Oncol. 2010;17:94-112.

Brownlee Z, Garg R, Listo M, et al. Late complications of radiation therapy for breast cancer: Evolution in techniques and risk over time. Gland Surg. 2018;7:371-378.

Luengo-Fernandez R, Leal J, Gray A, et al. Economic burden of cancer across the European Union: A population-based cost analysis. Lancet Oncol. 2013;14:1165-1174.

Gauthier G, Gagnon-Sanschagrin P, Guérin A, et al. Economic burden of HR+/HER2- metastatic breast cancer among adult premenopausal women. Adv Ther. 2018;35:503-514.

Roine E, Färkkilä N, Sintonen H, et al. Costs in different states of breast cancer. Anticancer Res. 2019;39:353-359.

Sun L, Legood R, Dos-Santos-Silva I, et al. Global treatment costs of breast cancer by stage: A systematic review. PLoS One. 2018;13:e0207993.

Ho PJ, Gernaat SAM, Hartman M, et al. Health-related quality of life in Asian patients with breast cancer: A systematic review. BMJ Open. 2018;8:e020512.

Alexander A, Kaluve R, Prabhu JS, et al. The impact of breast cancer on the patient and the family in Indian perspective. Indian J Palliat Care. 2019; 25:66-72.

Cardoso F, van’t Veer LJ, Bogaerts J, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717-729.

Filipits M, Rudas M, Jakesz R, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011;17:6012-6020.

Batra A, Patel A, Gupta VG, et al. Oncotype DX: Where does it stand in India? J Glob Oncol. 2019;5:1-2.

Alexander A, Kaluve R, Prabhu JS, et al. The impact of breast cancer on the patient and the family in Indian perspective. Indian J Palliat Care. 2019;25: 66-72.

Ho PJ, Gernaat SAM, Hartman M, et al. Health-related quality of life in Asian patients with breast cancer: A systematic review. BMJ Open. 2018;8: e020512.

Sun L, Legood R, Dos-Santos-Silva I, et al. Global treatment costs of breast cancer by stage: A systematic review. PLoS One. 2018;13:e0207993.

Roine E, Färkkilä N, Sintonen H, et al. Costs in different states of breast cancer. Anticancer Res. 2019;39:353- 359.

Vondeling GT, Menezes GL, Dvortsin EP, et al. Burden of early, advanced and metastatic breast cancer in the Netherlands. BMC Cancer. 2018;18: 262.

Brownlee Z, Garg R, Listo M, et al. Late complications of radiation therapy for breast cancer: Evolution in techniques and risk over time. Gland Surg. 2018;7:371-378.

Suwankhong D, Liamputtong P. Physical and emotional experiences of chemotherapy: A qualitative study among women with breast cancer in southern Thailand. Asian Pac J Cancer Prev. 2018;19:521-528.

Ruggiero A, Rizzo D, Catalano M, et al. Hypersensitivity to carboplatin in children with malignancy. Front Pharmacol. 2017; 8:201.

Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34:1134-1150.

Odle TG. Adverse effects of breast cancer treatment . Radiol Technol. 2014;85:297M-319M, quiz 320M-323M.

Zubair M, Wang S, Ali N. Advanced approaches to breast cancer classification and diagnosis. Frontiers in Pharmacology. 2021;11:632079.